Aptilon Corporation Increases Revenue 
for the Four-Month Period Ended December 31, 2006

• January 1 to March 31, 2007 revenues were $2,245,425 an increase of 135% compared to $960,122 for the same period in 2006
• Gross profit totaled $708,481 for Q3 2007, up 80% compared to Q3 2006
• Completed public offering of 25,000,000 common shares, at a price of $0.40 per share, raising net proceeds of $9.1 million
• Signed one-year renewal agreement with Merck & Co.
• Signed agreement with Ortho-McNeil Neurologics, Inc. for AxcelRx^SM Live Video Detailing Sales Channel

Montreal, Quebec, April 30, 2007 - Aptilon Corporation (TSX-V: APZ) announced today results for the four-month period ended December 31, 2006. Complete financial statements and MD&A are available on SEDAR at sedar.com. Revenues for that period were $1,523,197. On an annualized basis to account for the change in fiscal year-end to December 31, 2006, that occurred in August 31, 2006, revenues were $4,569,591. For the twelve-month period ended August 31, 2006, revenues were at $4,112,713 compared to $1,891,903 for the same period in 2005 for a net increase of 117%. The current run rate of $4,569,591 represents an increase of 141% over for the fiscal year ended August 31, 2005.

The net loss for the four-month period ended December 31, 2006 was $1,771,134 which represents a basic loss per share of $0.0528 (based on a weighted average number of common shares outstanding during the period of 33,517,674. The current number of outstanding shares is 139,143,600.) The operating loss for the four-month period ended December 31, 2006 is attributed to additional financing for the growth of physician access and the incremental commitment in direct sales efforts. At year end, December 31, 2006, the company's working capital position had increased to $6,542,888.

“2006 was a significant year. We completed the previously announced Qualifying Transaction and Public Offering and increased penetration of our solutions to enhance interactions between pharmaceutical companies and physicians with some of the world’s top pharmaceutical brands.” said Denis Martineau, President of Aptilon. “We generated thousands of successful sales and marketing interactions with targeted physicians via Aptilon’s ReachNet recruiting network, more than at any point in the company’s history,” Martineau added.

“With the release of our electronic signature and sampling product and the integration of multiple types of sales and marketing interaction solutions under one umbrella, we intend to continue to build upon our leadership position in this emerging market and drive further interaction growth.” Martineau adds. “In 2007, we will continue to focus on increasing pharmaceutical sales and marketing effectiveness by providing critical access to target physicians and increasing the volume of interactions generated on behalf of our pharmaceutical sales and marketing clients.”

About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with physicians via the Internet through its innovative AxcelRx Live video detailing (with company reps), virtual programs, e-Sampling, peer selling and other sales and marketing programs. Leading healthcare companies have adopted Aptilon’s “Sales Force of the Future” model, driving tens of thousands of high-quality rep-physician interactions averaging eight to 10 minutes in length. Aptilon provides the infrastructure necessary for sales representatives to build physician awareness, understanding and preference during all stages of a products life cycle, from pre-launch education through end stage support. For more information, visit www.aptilon.com.

Forward-looking Statements
This news release contains forward-looking information. These statements relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management of Aptilon. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and Aptilon does not assume any obligation to update or revise them to reflect new events or circumstances.